加拿大晕厥风险评分在急诊科的多中心验证
这项前瞻性多中心队列研究在加拿大9家急诊科纳入3819例16岁及以上、晕厥后24小时内就诊的患者,验证CSRS对30天严重结局的预测能力。139例(3.6%)发生30天严重结局,其中13例(0.3%)死亡。验证队列中预测风险与观察风险无差异,校准斜率为1.0,AUC为0.91(95%CI 0.88-0.93)。30天严重结局比例从极低危组的3/1631(0.3%)升至极高危组的40/78(51.3%),趋势检验P<.001;阈值评分-1时敏感度97.8%、特异度44.3%。作者推荐使用CSRS指导急诊管理。
要点
- CSRS在3819例急诊晕厥患者中验证,30天严重结局139例(3.6%),AUC 0.91(95%CI 0.88-0.93),校准斜率1.0。
- 30天严重结局比例从极低危组3/1631(0.3%)升至极高危组40/78(51.3%),趋势检验P<.001。
- 极低危和低危患者无死亡或室性心律失常发生。
- 阈值评分-1(2145/3819例)时,CSRS敏感度97.8%(95%CI 93.8%-99.6%),特异度44.3%(95%CI 42.7%-45.9%)。
- 作者推荐使用CSRS指导急诊管理:极低危和低危患者通常可出院,高危患者可考虑短期住院。
适用人群与场景
- 16岁及以上、晕厥后24小时内就诊于急诊科的患者,纳入9家加拿大急诊科的前瞻性多中心队列。
诊断标准与关键阈值
- 加拿大晕厥风险评分(CSRS)用于预测30天严重结局;阈值评分-1时敏感度97.8%、特异度44.3%。
- 30天严重结局包括心律失常性(心律失常、心律失常干预或不明原因死亡)和非心律失常性(心肌梗死、结构性心脏病、肺栓塞或出血)结局。
处置流程与药物剂量
- 作者推荐使用CSRS指导急诊管理,适用于急诊初步评估未发现严重病因的患者。
- 极低危和低危患者通常可出院。
- 高危患者可考虑短期住院。
研究设计与关键结果
- 前瞻性多中心队列研究,纳入9家加拿大急诊科3819例患者,平均年龄53.9岁(SD 22.8),女性2088例(54.7%)。
- 139例(3.6%)发生30天严重结局,其中13例(0.3%)死亡。
- 验证队列中预测风险与观察风险无差异:观察概率3.64%(95%CI 3.09%-4.28%)vs 模型预测概率3.17%(95%CI 2.66%-3.77%),P=.26;校准斜率1.0;AUC 0.91(95%CI 0.88-0.93)。
- 30天严重结局比例从极低危组3/1631(0.3%)升至极高危组40/78(51.3%),Cochran-Armitage趋势检验P<.001;严重结局亚型随CSRS风险类别升高呈类似显著增加。
- 极低危和低危患者无死亡或室性心律失常。
- 阈值评分-1(2145/3819例)时,敏感度97.8%(95%CI 93.8%-99.6%),特异度44.3%(95%CI 42.7%-45.9%)。
证据类型、等级与局限
- 证据类型:前瞻性多中心队列验证研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为CSRS实施有可能改善患者安全和医疗效率。
- 作者推荐使用CSRS指导急诊管理,适用于急诊初步评估未发现严重病因的晕厥患者;极低危和低危患者通常可出院,高危患者可考虑短期住院。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The management of patients with syncope in the emergency department (ED) is challenging because no robust risk tool available has been recommended for clinical use.
OBJECTIVE: To validate the Canadian Syncope Risk Score (CSRS) in a new cohort of patients with syncope to determine its ability to predict 30-day serious outcomes not evident during index ED evaluation.
DESIGN, SETTING, AND PARTICIPANTS: This prospective multicenter cohort study conducted at 9 EDs across Canada included patients 16 years and older who presented to EDs within 24 hours of syncope. Patients were enrolled from March 2014 to April 2018.
MAIN OUTCOMES AND MEASURES: Baseline characteristics, CSRS predictors, and 30-day adjudicated serious outcomes, including arrhythmic (arrhythmias, interventions for arrhythmia, or unknown cause of death) and nonarrhythmic (myocardial infarction, structural heart disease, pulmonary embolism, or hemorrhage) serious outcomes, were collected. Calibration and discrimination characteristics for CSRS validation were calculated.
RESULTS: A total of 3819 patients were included (mean [SD] age 53.9 [22.8] years; 2088 [54.7%] female), of whom 139 (3.6%) experienced 30-day serious outcomes, including 13 patients (0.3%) who died. In the validation cohort, there were no differences between the predicted and observed risk, the calibration slope was 1.0, and the area under the receiver operating characteristic curve was 0.91 (95% CI, 0.88-0.93). The empirical probability of a 30-day serious outcome during validation was 3.64% (95% CI, 3.09%-4.28%) compared with the model-predicted probability of 3.17% (95% CI, 2.66%-3.77%; P = .26). The proportion of patients with 30-day serious outcomes increased from 3 of 1631 (0.3%) in the very-low-risk group to 40 of 78 (51.3%) in the very-high-risk group (Cochran-Armitage trend test P < .001). There was a similar significant increase in the serious outcome subtypes with increasing CSRS risk category. None of the very-low-risk and low-risk patients died or experienced ventricular arrhythmia. At a threshold score of -1 (2145 of 3819 patients), the CSRS sensitivity and specificity were 97.8% (95% CI, 93.8%-99.6%) and 44.3% (95% CI, 42.7%-45.9%), respectively.
CONCLUSIONS AND RELEVANCE: The CSRS was successfully validated and its use is recommended to guide ED management of patients when serious causes are not identified during index ED evaluation. Very-low-risk and low-risk patients can generally be discharged, while brief hospitalization can be considered for high-risk patients. We believe CSRS implementation has the potential to improve patient safety and health care efficiency.
参考来源
- Thiruganasambandamoorthy V, Sivilotti MLA, Le Sage N, et al. Multicenter Emergency Department Validation of the Canadian Syncope Risk Score. JAMA Intern Med. 2020. PMID: 32202605. doi:10.1001/jamainternmed.2020.0288
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。